MADRIGAL PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
MDGL$432.79+8.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(288,284) | $(465,892) | $(373,630) |
| Other comprehensive income: | |||
| Net unrealized gain on available-for-sale securities | 392 | — | 500 |
| Foreign currency translation gain | 13 | — | — |
| Total other comprehensive income | 405 | — | 500 |
| Comprehensive loss | $(287,879) | $(465,892) | $(373,130) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.